Wells Fargo & Company Verona Pharma PLC Transaction History

Wells Fargo & Company

$507 Billion
Q3 2025

A detailed history of Wells Fargo & Company transactions in Verona Pharma PLC stock. As of the latest transaction made, Wells Fargo & Company holds 35,920 shares of VRNA stock, worth $3.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,920

Previous 56,653 36.6%

Holding current value

$3.84 Million

Previous $5.36 Million 28.5%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$90.08 - $106.69 $1.87 Million - $2.21 Million	-20,733 Reduced 36.6%	35,920 $3.83 Million
Q2 2025 Aug 14, 2025	SELL	$53.9 - $98.68 $551,828 - $1.01 Million	-10,238 Reduced 15.31%	56,653 $5.36 Million
Q1 2025 May 13, 2025	SELL	$44.81 - $69.63 $10,530 - $16,363	-235 Reduced 0.35%	66,891 $4.25 Million
Q4 2024 Feb 12, 2025	BUY	$28.71 - $47.02 $412,333 - $675,301	14,362 Added 27.22%	67,126 $3.12 Million
Q3 2024 Nov 13, 2024	SELL	$15.46 - $30.16 $433,776 - $846,229	-28,058 Reduced 34.72%	52,764 $1.52 Million

Q2 2024 Aug 13, 2024	BUY	$11.48 - $17.02 $236,843 - $351,139	20,631 Added 34.28%	80,822 $1.17 Million
Q1 2024 May 10, 2024	BUY	$15.3 - $20.24 $652,284 - $862,891	42,633 Added 242.81%	60,191 $968,000
Q4 2023 Feb 09, 2024	BUY	$11.94 - $20.47 $39,855 - $68,328	3,338 Added 23.47%	17,558 $349,000
Q3 2023 Nov 13, 2023	BUY	$16.3 - $22.09 $26,080 - $35,344	1,600 Added 12.68%	14,220 $231,000
Q2 2023 Aug 15, 2023	BUY	$19.41 - $23.43 $240,684 - $290,532	12,400 Added 5636.36%	12,620 $266,000
Q1 2023 May 12, 2023	BUY	$18.06 - $25.27 $361 - $505	20 Added 10.0%	220 $4,000
Q4 2022 Feb 13, 2023	BUY	$9.84 - $26.13 $984 - $2,613	100 Added 100.0%	200 $5,000
Q3 2022 Nov 14, 2022	BUY	$4.14 - $13.59 $413 - $1,359	100 New	100 $1,000

Others Institutions Holding VRNA

# of Institutions

273

Shares Held

77.1M

Call Options Held

686K

Put Options Held

442K

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $6.52B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Verona Pharma PLC Transaction History